

Federica Piccardi

ISTRUZIONE

2007-2010: Laurea magistrale in Biotecnologie

ESPERIENZE PROFESSIONALI

Dal 2008 lavora presso struttura SPF dell' ISTITUTO ITALIANO DI TECNOLOGIA (Genova)

BIBLIOGRAFIA

Spherical polymeric nanoconstructs for combined chemotherapeutic and anti-inflammatory therapies.

Lee A, Di Mascolo D, Francardi M, Piccardi F, Bandiera T, Decuzzi P.

Nanomedicine. 2016 Oct;12(7):2139-2147. doi: 10.1016/j.nano.2016.05.012. Epub 2016 May 28.

Bone turnover in wild type and pleiotrophin-transgenic mice housed for three months in the International Space Station (ISS).

Tavella S, Ruggiu A, Giuliani A, Brun F, Canciani B, Manescu A, Marozzi K, Cilli M, Costa D, Liu Y, Piccardi F, Tasso R, Tromba G, Rustichelli F, Cancedda R.

PLoS One. 2012;7(3):e33179. doi: 10.1371/journal.pone.0033179. Epub 2012 Mar 15.

Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides.

Brignole C, Marimpietri D, Pastorino F, Di Paolo D, Pagnan G, Loi M, Piccardi F, Cilli M, Tradori-Cappai A, Arrigoni G, Pistoia V, Ponzoni M.

J Control Release. 2009 Sep 1;138(2):122-7. doi: 10.1016/j.jconrel.2009.05.006. Epub 2009 May 7.

PNAEmu can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease.

Matis S, Mariani MR, Cutrona G, Cilli M, Piccardi F, Daga A, Damonte G, Millo E, Moroni M, Roncella S, Fedeli F, Boffa LC, Ferrarini M.

Cancer Gene Ther. 2009 Oct;16(10):786-93. doi: 10.1038/cgt.2009.26. Epub 2009 Apr 10.

The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.

Pagnan G, Di Paolo D, Carosio R, Pastorino F, Marimpietri D, Brignole C, Pezzolo A, Loi M, Galiotta LJ, Piccardi F, Cilli M, Nico B, Ribatti D, Pistoia V, Ponzoni M.

Clin Cancer Res. 2009 Feb 15;15(4):1199-209. doi: 10.1158/1078-

Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation.

Paleari L, Catassi A, Ciarlo M, Cavalieri Z, Bruzzo C, Servent D, Cesario A, Chessa L, Cilli M, Piccardi F, Granone P, Russo P.

Cell Prolif. 2008 Dec;41(6):936-59. doi: 10.1111/j.1365-2184.2008.00566.x. Erratum in: Cell

Prolif. 2009 Aug;42(4):568. Cell Prolif. 2009 Feb;42(1):122.

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, Baio G, Neumaier CE, Brignole C, Loi M, Marimpietri D, Pagnan G, Cilli M, Lepekhin EA, Garde SV, Longhi R, Corti A, Allen TM, Wu JJ, Ponzoni M.

Clin Cancer Res. 2008 Nov 15;14(22):7320-9. doi: 10.1158/1078-0432.CCR-08-0804.

A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity.

Ponassi R, Biasotti B, Tomati V, Bruno S, Poggi A, Malacarne D, Cimoli G, Salis A, Pozzi S, Miglino M, Damonte G, Cozzini P, Spyraakis F, Campanini B, Bagnasco L, Castagnino N, Tortolina L, Mumot A, Frassoni F, Daga A, Cilli M, Piccardi F, Monfardini I, Perugini M, Zoppoli G, D'Arrigo C, Pesenti R, Parodi S.

Cell Cycle. 2008 Oct;7(20):3211-24. Epub 2008 Oct 20. Erratum in: Cell Cycle. 2012 Oct 1;11(19):3703. Spyraakis, Francesca [corrected to Spyraakis, Francesca].

Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase.

Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F.

PLoS One. 2008 Jul 9;3(7):e2599. doi: 10.1371/journal.pone.0002599.

Preclinical ex vivo expansion of peripheral blood CD34+ selected cells from cancer patients mobilized with combination chemotherapy and granulocyte colony-stimulating factor.

Lorenzon D, Mazzucato M, Abbruzzese L, Cilli M, De Angeli S, Degan M, Mambrini G, Piccardi F, Rupolo M, Michieli M, De Marco L, Gattei V, Astori G.

Vox Sang. 2008 May;94(4):342-50. doi: 10.1111/j.1423-0410.2008.01038.x. Epub 2008 Feb 14.

Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.

Bertino P, Piccardi F, Porta C, Favoni R, Cilli M, Mutti L, Gaudino G.

Clin Cancer Res. 2008 Jan 15;14(2):541-8. doi: 10.1158/1078-0432.CCR-07-1388.

Ligand-targeted liposomal therapies of neuroblastoma.

Pastorino F, Marimpietri D, Brignole C, Di Paolo D, Pagnan G, Daga A, Piccardi F, Cilli M, Allen TM, Ponzoni M.

Curr Med Chem. 2007;14(29):3070-8. Review.

Natural agents targeting the alpha7-nicotinic-receptor in NSCLC: a promising prospective in anti-cancer drug development.

Grozio A, Paleari L, Catassi A, Servent D, Cilli M, Piccardi F, Paganuzzi M, Cesario A, Granone P, Mourier G, Russo P.

Int J Cancer. 2008 Apr 15;122(8):1911-5.

Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.

Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F, Cilli M, Di Paolo D, Pagnan G, Longo L, Perri P, Ribatti D, Ponzoni M.

Clin Cancer Res. 2007 Jul 1;13(13):3977-88.

Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.

Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M.

Cancer Res. 2006 Oct 15;66(20):10073-82.

Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.

Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M.

J Natl Cancer Inst. 2006 Aug 16;98(16):1142-57.